WHI-P154, 表皮生长因子受体抑制剂 Janus 激酶 1 抑制剂 Janus 激酶 2 抑制剂 Janus 激酶 3 抑制剂

CAS: 211555-04-3 货号: W408378 分子式: C16H14BrN3O3 分子量: 376.2 EC号: 809-014-9 PubChem CID: 3795
有货
级别和纯度: Moligand™ ? Moligand™ —— 阿拉丁的配体和生物活性小分子系列。适用于需要明确小分子工具的受体、通路和结合研究。 10mM in DMSO
储存条件
-80℃储存
运输条件
特低温运输
★
规格
库存
价格
数量
1ml
W408378-1ml
现货 Stock Image
¥451.90
请输入您要添加的产品数量

概述

WHI-P154是一种有效的JAK3抑制剂,IC50为1.8 μM,对JAK1和JAK2没有抑制活性,也抑制EGFR, Src, Abl, VEGFR和MAPK,抑制Stat3而非Stat5磷酸化A JAK3 inhibitor which inhibits other common kinases.

Information

WHI-P154 is a potentJAK3inhibitor withIC50of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
In vitro

WHI-P154 is first described as a JAK3 inhibitor that displays no activity at JAK1 or JAK2. WHI-P154 inhibits STAT1 activation, iNOS expression and NO production in macrophages in vitro. But it is proved that WHI-P154 also inhibits other common kinases including EGFR, Src, Abl, VEGFR, MAPK and PI3-K and induces apoptosis in human glioblastoma cell lines. WHI-P154 inhibits glioblastoma cell adhesion and migration in the context of ECM. WHI-P154 exhibits significant cytotoxicity against U373 and U87 human glioblastoma cell lines, causing apoptotic cell death at micromolar concentrations. The in vitro antiglioblastoma activity of WHI-P154 is amplified > 200-fold and rendered selective by conjugation to recombinant human epidermal growth factor (EGF). In vitro treatment with EGF-P154 results killing of glioblastoma cells at nanomolar concentrations with an IC50 of 813 nM, whereas no cytotoxicity against EGF-R-negative leukemia cellsis observed, even at concentrations as high as 100 mM.

In vivo

The in vivo administration of EGF-P154 results in delayed tumor progression and improved tumor-free survival in a severe combined immunodeficient mouse glioblastoma xenograft model. Whereas none of the control mice remain alive tumor-free beyond 33 days (median tumor-free survival, 19 days) and all control mice have tumors that rapidly progress to reach an average size of > 500 mm3 by 58 days, 40% of mice treated for 10 consecutive days with 1 mg/kg/day EGF-P154 remain alive and free of detectable tumors for more than 58 days with a median tumor-free survival of 40 days. The tumors developing in the remaining 60% of the mice never reache a size > 50 mm3.
Cell Data

cell lines:

Concentrations:0.1-250 μM

Incubation Time:24-36 h

Powder Purity:≥99%

规格

英文别名
Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]-
规格或纯度
Moligand™, 10mM in DMSO
英文名称
WHI-P154
生化机理
WHI-P154 是一种强效的 JAK3 抑制剂,IC50 为 1.8 μM,对 JAK1 或 JAK2 没有活性,还能抑制表皮生长因子受体(EGFR)、Src、Abl、血管内皮生长因子受体(VEGFR)和 MAPK,阻止 Stat3 磷酸化,但不能阻止 Stat5 磷酸化。
储存条件
-80℃储存
运输条件
特低温运输
作用类型
抑制剂
作用机制
表皮生长因子受体抑制剂 Janus 激酶 1 抑制剂 Janus 激酶 2 抑制剂 Janus 激酶 3 抑制剂
名称和识别符
EC号
809-014-9
分子类型
小分子
Isomeric SMILES
COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)O)Br)OC
PubChem CID
分子量
376.2

高级数据

关联靶点(人)
EGFR Tclin 表皮生长因子受体(Epidermal growth factor receptor) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
JAK3 Tclin 酪氨酸蛋白激酶JAK3(Tyrosine-protein kinase JAK3) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
JAK1 Tclin 酪氨酸蛋白激酶JAK1(Tyrosine-protein kinase JAK1) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
ABCG2 Tchem ATP 结合盒亚家族 G 成员 2(ATP-binding cassette sub-family G member 2) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
JAK2 Tclin 酪氨酸蛋白激酶JAK2(Tyrosine-protein kinase JAK2) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
化学和物理性质
溶解性
Solubility (25°C) In vitro DMSO: 16 mg/mL (72.65 mM);    
熔点
230 °C
安全和危险性(GHS)
WGK Germany
3
质检证书(CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器

需要帮助选择级别?

我们的级别选择指南涵盖了目录中所有的变体的纯度、稳定剂状态和应用适用性。

查看 Moligand™ 级别指南 →